Article
Regenerative Treatment Designed to Increase Drug Exposure Through the Cochlea; Study Results Expected in H2 2023 Frequency’s Lead Hearing Program, FX-322, on Track for Phase 2b Topline Results in Q1 2023 Excerpt from the Press Release: LEXINGTON, Mass.–(BUSINESS WIRE)–Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a…
Read More
Complete responses were observed in patients who received at least three previous lines of treatment (including CAR-T’s) Recent clinical data add to the growing enthusiasm for the therapeutic potential of cancer vaccines in combination with checkpoint inhibitors Oral presentation of the clinical data at the Immuno-Oncology 360° conference in February 2023 Excerpt from the Press…
Read More
– Topline data for pivotal Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia expected in mid-2023 – Brilaroxazine is a serotonin/dopamine modulator with a differentiated pharmacological and safety profile Excerpt from the Press Release: CUPERTINO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical…
Read More
RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye Excerpt from the Press Release: REDWOOD CITY, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody drug conjugates (ADCs), today announced preliminary safety and efficacy data from its Phase 2 ACE‑Breast-03 study during a Spotlight Poster Presentation at the 2022 San…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented updated interim data from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma (RRMM) in a poster presentation at the 64th American Society…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Electra Therapeutics, Inc., a clinical stage biotechnology company developing novel antibody therapies that target signal regulatory proteins (SIRP), today announced presentations and clinical progress for ELA026, the company’s first-in-class antibody in development for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening inflammatory disease. Three poster…
Read More
Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases Corvus confirms plans to initiate a Phase 2 clinical trial of CPI-818 in T cell lymphoma and a Phase 1 clinical trial in atopic dermatitis,…
Read More
Oral presentation describes a unique APC nanobody library and its potential as a source for novel treatments to diseases including trauma, hemophilia, ischemia and sepsis. Excerpt from the Press Release: SAN FRANCISCO, Dec. 11, 2022 /PRNewswire/ — Coagulant Therapeutics Corporation, a privately held company focused on the design, development and commercialization of therapeutics targeted to…
Read More
BMF-500, an investigational third generation covalent FLT3 inhibitor, demonstrated preclinically: Biomea Fusion remains on track to file an IND for BMF-500 in the first half of 2023 Excerpt from the Press Release: REDWOOD CITY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing…
Read More